MX382116B - Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas. - Google Patents

Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.

Info

Publication number: MX382116B
Authority: MX; Mexico
Prior art keywords: hepe; treating; methods; same; compositions
Prior art date: 2014-12-02

Application number

MX2017007000A

Other languages

English (en)

Spanish (es)

Other versions

MX2017007000A (es

Inventor

John Climax

Jonathan Rowe

Kevin Duffy

Original Assignee

Afimmune Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-12-02

Filing date

2015-12-02

Publication date

2025-03-13

2015-12-02 Application filed by Afimmune Ltd filed Critical Afimmune Ltd

2017-12-07 Publication of MX2017007000A publication Critical patent/MX2017007000A/es

2025-03-13 Publication of MX382116B publication Critical patent/MX382116B/es

Links

206010016654 Fibrosis Diseases 0.000 title abstract 2
230000004761 fibrosis Effects 0.000 title abstract 2
239000000203 mixture Substances 0.000 title abstract 2
OWFVSJHRFRIEAK-UHFFFAOYSA-N 15-hydroxyicosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCC(O)CCCC=CC=CC=CC=CC=CC(O)=O OWFVSJHRFRIEAK-UHFFFAOYSA-N 0.000 title 1
WLKCSMCLEKGITB-XWJJKCKWSA-N 15-HEPE Chemical compound CC\C=C/CC(O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O WLKCSMCLEKGITB-XWJJKCKWSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pulmonology (AREA)
Emergency Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MX2017007000A 2014-12-02 2015-12-02 Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas. MX382116B (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462086535P	2014-12-02	2014-12-02
PCT/US2015/063488 WO2016090030A1 (en)	2014-12-02	2015-12-02	Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same

Publications (2)

Publication Number	Publication Date
MX2017007000A MX2017007000A (es)	2017-12-07
MX382116B true MX382116B (es)	2025-03-13

Family

ID=56092410

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MX2017007000A MX382116B (es)	2014-12-02	2015-12-02	Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
MX2021005080A MX2021005080A (es)	2014-12-02	2017-05-29	Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
MX2021005080A MX2021005080A (es)	2014-12-02	2017-05-29	Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.

Country Status (17)

Country	Link
US (1)	US10363235B2 (2)
EP (2)	EP3226873B1 (2)
JP (2)	JP6986445B2 (2)
KR (1)	KR20170102879A (2)
CN (2)	CN107206008A (2)
AU (2)	AU2015358512B2 (2)
BR (1)	BR112017011685A2 (2)
CA (1)	CA2968980A1 (2)
ES (1)	ES2900593T3 (2)
IL (2)	IL252431B (2)
MA (1)	MA41120A (2)
MX (2)	MX382116B (2)
PH (1)	PH12017501022B1 (2)
RU (2)	RU2721555C2 (2)
SG (2)	SG11201704495VA (2)
WO (1)	WO2016090030A1 (2)
ZA (2)	ZA201704463B (2)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201301626D0 (en) *	2013-01-30	2013-03-13	Dignity Sciences Ltd	Composition comprising 15-OHEPA and methods of using the same
JP2016538288A (ja)	2013-11-15	2016-12-08	ディグニティサイエンシスリミテッド	多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
EP3091959A4 (en) *	2014-01-10	2017-09-20	Dignity Sciences Limited	Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
US20180008567A1 (en) *	2015-01-16	2018-01-11	Afimmune Limited	Compositions comprising 15-hepe and methods of using the same
MA47141A (fr)	2015-05-13	2019-11-06	Ds Biopharma Ltd	Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation
CA3129008A1 (en) *	2015-12-18	2017-06-22	Afimmune Limited	Compositions comprising 15-hepe and methods of using the same
US20210315851A1 (en)	2020-04-03	2021-10-14	Afimmune Limited	Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6180671B1 (en) *	1998-03-10	2001-01-30	Beth Israel Deaconess Medical Center, Inc.	Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected
JP2000191525A (ja)	1998-12-25	2000-07-11	Nof Corp	皮膚外用剤組成物
WO2001049282A2 (en) *	2000-01-06	2001-07-12	Martek Biosciences Corporation	Therapeutic preparations of highly unsaturated fatty acids
EP1762557B1 (en)	2000-02-16	2011-04-06	The Brigham And Women's Hospital, Inc.	Aspirin-triggered lipid mediators
JP2005179211A (ja)	2003-12-17	2005-07-07	Idemitsu Kosan Co Ltd	皮膚外用剤組成物
EP1711173A2 (en)	2003-12-31	2006-10-18	Igennus Limited	Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof
WO2005102309A2 (en)	2004-04-26	2005-11-03	Ltb4 Sweden Ab	In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
EP3285072B1 (en) *	2006-08-08	2020-04-15	Metabolon, Inc.	Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
US8042070B2 (en) *	2007-10-23	2011-10-18	International Business Machines Corporation	Methods and system for analysis and management of parametric yield
GB0802116D0 (en) *	2008-02-05	2008-03-12	Natural Enviromental Res Counc	Treatment
PE20100156A1 (es) *	2008-06-03	2010-02-23	Boehringer Ingelheim Int	Tratamiento de nafld
US20110105510A1 (en)	2008-06-17	2011-05-05	Hiroshi Ishikawa	Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
WO2010120880A1 (en) *	2009-04-14	2010-10-21	Vertex Pharmaceuticals Incorporated	Treatment of liver diseases with a caspase inhibitor
GB0907413D0 (en)	2009-04-29	2009-06-10	Equateq Ltd	Novel methods
US10154977B2 (en) *	2011-03-25	2018-12-18	The Brigham And Women's Hospital, Inc.	Anti-inflammatory particles
US20120264824A1 (en) *	2011-04-15	2012-10-18	Mochida Pharmaceutical Co., Ltd.	Compositions and methods for treating non-alcoholic steatohepatitis
MX360979B (es) *	2011-09-16	2018-11-22	Galectin Therapeutics Inc	Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y de la enfermedad del higado graso no alcohólico.
RU2014119948A (ru)	2011-10-19	2015-11-27	Дигнити Сайенсиз Лимитед	ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ DGLA И/ИЛИ 15-HETrE, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US8293790B2 (en)	2011-10-19	2012-10-23	Dignity Sciences Limited	Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
JP2015500639A (ja)	2011-11-29	2015-01-08	ディグニティサイエンシスリミテッド	２０−炭素脂肪酸を含む組成物ならびにその製造方法および使用方法
CN104302305A (zh) *	2011-12-16	2015-01-21	塔瑞克斯制药有限公司	用于治疗纤维化的血管紧张素
US20120264705A1 (en)	2012-01-26	2012-10-18	Dignity Sciences Limited	Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en)	2012-02-23	2013-10-10	Dignity Sciences Limited	Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
DK2858496T3 (da)	2012-05-10	2023-07-24	Solutex Na Llc	Olier med anti-inflammatorisk aktivitet, som indeholder naturlige specialiserede pro-afhjælpningsmediatorer og deres forløbere
GB201301626D0 (en) *	2013-01-30	2013-03-13	Dignity Sciences Ltd	Composition comprising 15-OHEPA and methods of using the same
TWI742541B (zh) *	2013-03-15	2021-10-11	英商邊緣生物科技有限公司	用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
CA3129008A1 (en)	2015-12-18	2017-06-22	Afimmune Limited	Compositions comprising 15-hepe and methods of using the same

2015
- 2015-12-01 MA MA041120A patent/MA41120A/fr unknown
- 2015-12-02 WO PCT/US2015/063488 patent/WO2016090030A1/en not_active Ceased
- 2015-12-02 CN CN201580074543.0A patent/CN107206008A/zh active Pending
- 2015-12-02 JP JP2017527848A patent/JP6986445B2/ja not_active Expired - Fee Related
- 2015-12-02 SG SG11201704495VA patent/SG11201704495VA/en unknown
- 2015-12-02 RU RU2017122758A patent/RU2721555C2/ru active
- 2015-12-02 SG SG10202010594WA patent/SG10202010594WA/en unknown
- 2015-12-02 EP EP15865150.5A patent/EP3226873B1/en active Active
- 2015-12-02 BR BR112017011685-5A patent/BR112017011685A2/pt not_active Application Discontinuation
- 2015-12-02 CA CA2968980A patent/CA2968980A1/en not_active Abandoned
- 2015-12-02 RU RU2020115523A patent/RU2020115523A/ru unknown
- 2015-12-02 KR KR1020177018195A patent/KR20170102879A/ko not_active Withdrawn
- 2015-12-02 CN CN202011279675.6A patent/CN112245419A/zh active Pending
- 2015-12-02 MX MX2017007000A patent/MX382116B/es unknown
- 2015-12-02 ES ES15865150T patent/ES2900593T3/es active Active
- 2015-12-02 AU AU2015358512A patent/AU2015358512B2/en not_active Ceased
- 2015-12-02 EP EP21200516.9A patent/EP3988101A1/en not_active Withdrawn
2016
- 2016-03-07 US US15/062,636 patent/US10363235B2/en active Active
2017
- 2017-05-22 IL IL252431A patent/IL252431B/en unknown
- 2017-05-29 MX MX2021005080A patent/MX2021005080A/es unknown
- 2017-06-01 PH PH12017501022A patent/PH12017501022B1/en unknown
- 2017-06-30 ZA ZA2017/04463A patent/ZA201704463B/en unknown
2018
- 2018-06-29 ZA ZA2018/04380A patent/ZA201804380B/en unknown
2021
- 2021-05-18 AU AU2021203189A patent/AU2021203189A1/en not_active Abandoned
- 2021-11-10 IL IL287983A patent/IL287983A/en unknown
- 2021-11-29 JP JP2021192836A patent/JP2022031813A/ja active Pending

Also Published As

Publication number	Publication date
IL287983A (en)	2022-01-01
CN107206008A (zh)	2017-09-26
ZA201704463B (en)	2018-11-28
ES2900593T3 (es)	2022-03-17
JP6986445B2 (ja)	2021-12-22
US20160184252A1 (en)	2016-06-30
MX2021005080A (es)	2021-06-15
IL252431B (en)	2021-12-01
US10363235B2 (en)	2019-07-30
MX2017007000A (es)	2017-12-07
RU2017122758A (ru)	2019-01-09
SG10202010594WA (en)	2020-12-30
IL252431A0 (en)	2017-07-31
MA41120A (fr)	2017-10-10
EP3226873A1 (en)	2017-10-11
CA2968980A1 (en)	2016-06-09
PH12017501022B1 (en)	2022-02-16
RU2020115523A (ru)	2021-01-27
RU2017122758A3 (2)	2019-06-13
EP3226873B1 (en)	2021-10-27
RU2721555C2 (ru)	2020-05-20
SG11201704495VA (en)	2017-06-29
PH12017501022A1 (en)	2017-11-27
JP2022031813A (ja)	2022-02-22
HK1245101A1 (zh)	2018-08-24
AU2015358512B2 (en)	2021-02-18
AU2021203189A1 (en)	2021-06-10
EP3226873A4 (en)	2018-08-08
AU2015358512A1 (en)	2017-07-20
KR20170102879A (ko)	2017-09-12
ZA201804380B (en)	2021-03-31
WO2016090030A1 (en)	2016-06-09
BR112017011685A2 (pt)	2018-01-02
JP2017536380A (ja)	2017-12-07
EP3988101A1 (en)	2022-04-27
CN112245419A (zh)	2021-01-22

Publication	Publication Date	Title
CY1124215T1 (el)	2022-05-27	Μκ2 αναστολεις και χρησεις αυτων
CO2017011535A2 (es)	2018-01-31	Composiciones de ácido obeticólico y métodos de uso
DK3121175T3 (da)	2020-03-09	1,3-benzodioxolderivater som ezh1- og/eller ezh2-hæmmere
PL3145522T3 (pl)	2021-06-14	Kombinacja, kompozycja i sposób podawania kombinacji lub kompozycji zwierzętom
HUE054159T2 (hu)	2021-08-30	HPK1 gátlók és azok alkalmazási módja
BR112016026378A2 (pt)	2017-12-05	formulações e métodos para tratamento com queratina
BR112018000729A2 (pt)	2018-09-04	métodos e composições para o aprimoramento de traços de plantas
PT3212225T (pt)	2026-02-26	Métodos e composições para células t modificadas
PT3204015T (pt)	2022-02-09	Composições e métodos para inibição de expressão do gene hao1 (hidroxiácido oxidase 1 (glicolato oxidase))
MX382116B (es)	2025-03-13	Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
MX381640B (es)	2025-03-04	Metodos y compuestos agonistas de gip.
MX2016017063A (es)	2018-01-12	Metodos y composiciones de acidos biliares y sales para la reduccion de grasa.
HUE054204T2 (hu)	2021-08-30	Összetételek és módszerek gyulladások kezeléséhez és megelõzéséhez
MX2016009590A (es)	2017-05-09	Composiciones de apilimod y métodos para usar las mismas.
DK3229840T5 (da)	2020-11-16	3,5-dihydroxy-4-isopropyl-trans-stilben til anvendelse i topisk behandling af akne
MX2021000773A (es)	2022-07-19	Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo.
MX2017006019A (es)	2017-09-13	Apilimod para uso en el tratamiento de melanoma.
BR112016026143A2 (pt)	2018-08-07	os métodos e composições compreendendo ácido 10-hidroxi-2-decenóico.
PL3250042T3 (pl)	2025-02-24	Kompozycja, sposób, zastosowanie i wyrób
DK3240821T3 (da)	2021-04-06	Lavdosis gashydrathæmmersammensætning og tilhørende fremgangsmåde
PL3373922T3 (pl)	2022-05-02	Kompozycje i sposoby do stosowania do leczenia homocystynurii
EA201691493A1 (ru)	2017-02-28	Замещенные n-арилпиридиноны
CL2019003571A1 (es)	2020-06-19	Lipido que comprende ácido docosapentanoico. (divisional solicitud 3351-2016)
PL3381938T3 (pl)	2021-07-05	Sposób zwiększania wydajności kolagenu i kolagen wytworzony przy jego użyciu
MX2017007492A (es)	2018-05-04	Prevención y tratamiento de condiciones inflamatorias.